Payment overview · 2025
General Payments
$742.99
39 reported records · 10 companies
Healthcare provider profile · identity verified
Juli Anne Ackerman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SHERIDAN, WY · NPI 1619292927
Verified facts
What the public records show
CMS Open Payments records show Juli Anne Ackerman, MD received $742.99 in general payments during 2025 across 39 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $173.89 | 23.4% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $145.55 | 19.6% | 12 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $114.44 | 15.4% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $108.61 | 14.6% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.23 | 6.8% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $49.52 | 6.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $37.43 | 5.0% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $25.57 | 3.4% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $23.70 | 3.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.05 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $742.99 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $145.55 | 12 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $145.55 | 12 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $131.56 | 7 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $114.44 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $108.61 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $50.23 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $49.52 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $37.43 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $25.57 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $25.57 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
86 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 696 | 188 |
| Losartan Potassium | Losartan Potassium | 477 | 136 |
| Atorvastatin Calcium | Atorvastatin Calcium | 439 | 129 |
| Amlodipine Besylate | Amlodipine Besylate | 390 | 109 |
| Omeprazole | Omeprazole | 325 | 104 |
| Gabapentin | Gabapentin | 313 | 102 |
| Pantoprazole Sodium | Pantoprazole Sodium | 289 | 89 |
| Lisinopril | Lisinopril | 240 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 211 | 66 |
| Simvastatin | Simvastatin | 194 | 53 |
| Trazodone Hcl | Trazodone Hcl | 189 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 185 | 58 |
| Potassium Chloride | Potassium Chloride | 179 | 60 |
| Eliquis | Apixaban | 178 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 170 | 55 |
| Celecoxib | Celecoxib | 168 | 56 |
| Ozempic | Semaglutide | 156 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 148 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 147 | 43 |
| Sertraline Hcl | Sertraline Hcl | 133 | 45 |
| Montelukast Sodium | Montelukast Sodium | 129 | 37 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 124 | 36 |
| Furosemide | Furosemide | 123 | 41 |
| Estradiol | Estradiol | 100 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 45 |
| Citalopram Hbr | Citalopram Hydrobromide | 93 | 26 |
| Pregabalin | Pregabalin | 90 | 29 |
| Tramadol Hcl | Tramadol Hcl | 90 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 87 | 19 |
| Farxiga | Dapagliflozin Propanediol | 86 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 22 |
| Spironolactone | Spironolactone | 83 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 82 | 25 |
| Bupropion Xl | Bupropion Hcl | 79 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 79 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 79 | 26 |
| Alendronate Sodium | Alendronate Sodium | 77 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 25 |
| Ezetimibe | Ezetimibe | 76 | 19 |
| Synthroid | Levothyroxine Sodium | 75 | 21 |
| Metformin Hcl | Metformin Hcl | 74 | 24 |
| Lorazepam | Lorazepam | 73 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 21 |
| Prednisone | Prednisone | 69 | 47 |
| Oxycodone Hcl | Oxycodone Hcl | 68 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 31 |
| Propranolol Hcl | Propranolol Hcl | 66 | 22 |
| Clonazepam | Clonazepam | 59 | 11 |
| Allopurinol | Allopurinol | 57 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 57 | 16 |
| Meloxicam | Meloxicam | 56 | 23 |
| Carvedilol | Carvedilol | 54 | 13 |
| Warfarin Sodium | Warfarin Sodium | 54 | 13 |
| Metformin Hcl Er | Metformin Hcl | 50 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 19 |
| Finasteride | Finasteride | 49 | 13 |
| Xarelto | Rivaroxaban | 49 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Atenolol | Atenolol | 44 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 36 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 14 |
| Buspirone Hcl | Buspirone Hcl | 43 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | suppressed |
| Topiramate | Topiramate | 38 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | 11 |
| Trulicity | Dulaglutide | 37 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 36 | 14 |
| Famotidine | Famotidine | 36 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 34 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | 14 |
| Baclofen | Baclofen | 32 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 22 |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | 11 |
| Alprazolam | Alprazolam | 28 | suppressed |
| Azithromycin | Azithromycin | 28 | 25 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Fluconazole | Fluconazole | 27 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Aripiprazole | Aripiprazole | 25 | 12 |
| Morphine Sulfate | Morphine Sulfate | 25 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 18 |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 12 |
| Belsomra | Suvorexant | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | 11 |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Nystatin | Nystatin | 18 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 15 |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Torsemide | Torsemide | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $742.99 · 39 records | AstraZeneca Pharmaceuticals LP | Arikayce, BREZTRI, Brinsupri, CAPLYTA, CAPVAXIVE, EVENITY, Flector, GARDASIL 9, Kerendia, Licart, MOUNJARO, PROLIA, TRELEGY ELLIPTA, Tirosint, Veozah, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error